Gyre Therapeutics, Inc. (NASDAQ:GYRE – Free Report) – Investment analysts at Noble Financial issued their Q2 2026 earnings estimates for Gyre Therapeutics in a research note issued on Friday, May 8th. Noble Financial analyst R. Leboyer anticipates that the company will post earnings of ($0.09) per share for the quarter. The consensus estimate for Gyre Therapeutics’ current full-year earnings is ($0.30) per share. Noble Financial also issued estimates for Gyre Therapeutics’ Q3 2026 earnings at ($0.13) EPS and Q4 2026 earnings at ($0.16) EPS.
Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last posted its earnings results on Thursday, March 12th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). Gyre Therapeutics had a positive return on equity of 3.13% and a negative net margin of 5.44%.The firm had revenue of $37.20 million during the quarter, compared to analysts’ expectations of $36.30 million.
Get Our Latest Analysis on GYRE
Gyre Therapeutics Price Performance
GYRE opened at $7.30 on Wednesday. The firm has a market capitalization of $708.32 million, a P/E ratio of -81.10 and a beta of 2.03. Gyre Therapeutics has a one year low of $6.57 and a one year high of $11.78. The company has a fifty day moving average price of $7.51 and a 200-day moving average price of $7.67.
Hedge Funds Weigh In On Gyre Therapeutics
Hedge funds have recently modified their holdings of the company. State of Alaska Department of Revenue bought a new stake in shares of Gyre Therapeutics during the 3rd quarter valued at $38,000. Bank of America Corp DE grew its holdings in Gyre Therapeutics by 28.8% during the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after purchasing an additional 1,402 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after purchasing an additional 2,961 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Gyre Therapeutics by 77.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after purchasing an additional 3,244 shares during the period. Finally, Dimensional Fund Advisors LP bought a new stake in Gyre Therapeutics during the 4th quarter valued at $77,000. 23.99% of the stock is currently owned by institutional investors.
Insider Activity
In related news, CEO Ying Luo sold 10,136 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total value of $81,493.44. Following the completion of the sale, the chief executive officer directly owned 2,565,226 shares of the company’s stock, valued at approximately $20,624,417.04. This represents a 0.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 10.00% of the company’s stock.
About Gyre Therapeutics
Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.
Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.
Featured Stories
- Five stocks we like better than Gyre Therapeutics
- Ally Financial Is Back to Basics—And Investors Are Watching
- Navitas Breaks Out on India Deal, Validating High-Power AI Pivot
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
